Aptinyx Inc. Company Review & Valuation
APTX
Nasdaq
Latest Price
0.59USD
Market Capitalization
40.02mUSD
About Aptinyx Inc.
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders.
It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
The company has a collaboration agreement with Allergan plc.
Aptinyx Inc.
was founded in 2015 and is headquartered in Evanston, Illinois.
Industry
Biotechnology
HQ Location
Evanston, Illinois
Stock Price
Price data not available for Aptinyx Inc..
Performance
Please login or create a free account to view the contents of this section.
Valuation
Please login or create a free account to view the contents of this section.
Financial Reports
Please login or create a free account to view the contents of this section.